大包装询价 产品介绍 引用文献(0) 评论(0)
物种
Rat分子别名
Siglec-2, CD22, BL-CAM, B-cell receptor CD22Accession
D3ZD88表达序列
Trp24-Arg692 with His Tag at C-Terminus
表达宿主
HEK293分子量
95-120kDa (Reducing)
纯度
＞95% by SDS-PAGE & SEC-HPLC内毒素含量
<0.1EU/μg标记
Unconjugated标签
His Tag性状
Lyophilized powder缓冲体系
PBS, PH7.4, 5% trehalose溶解方法
Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation.
储存条件
· 12 months from date of receipt, lyophilized powder stored at -20 to -80℃.
· 3 months, -20 to -80℃ under sterile conditions after reconstitution.
· 1 week, 2 to 8℃ under sterile conditions after reconstitution.
· Please avoid repeated freeze-thaw cycles.文献引用
1、Tedder T F. et al. (2005) CD22: a multifunctional receptor that regulates B lymphocyte survival and signal transduction. Adv Immunol. 88: 1-50.
2、Fujimoto M. et al. (2007) B cell signaling and autoimmune diseases: CD19/CD22 loop as a B cell signaling device to regulate the balance of autoimmunity. J Dermatol Sci. 46(1): 1-9.
3、Walker J A. et al. (2008) CD22: an inhibitory enigma. Immunology. 123(3): 314-325.
4、Nitschke L. (2009) CD22 and Siglec-G: B-cell inhibitory receptors with distinct functions. Immunol Rev. 230(1): 128-143.
Siglec-2, also known as CD22, is a member of the immune inhibitory Siglecs family, which carries ITIM motifs to transmit immunosuppressive signals. These signals result in reduced phagocytosis, diminished inflammation, and inhibition of danger-associated molecular pattern (DAMP)/pathogen-associated molecular pattern (PAMP)-mediated inflammation.
Siglec-2 is a cell surface receptor predominantly expressed on B cells, where it regulates B-cell proliferation, survival, signaling, and antibody production. The cytoplasmic tail of Siglec-2 contains six tyrosine residues, four of which are located within ITIM motifs: Y783, Y843, Y863, and Y828. Upon cross-linking of B-cell receptors (BCRs), these tyrosine residues become phosphorylated, recruiting Src homology region 2 (SH2) domain-containing protein tyrosine phosphatase-1 (SHP-1). This recruitment leads to the dephosphorylation of BCR-proximal signaling complexes.
Given its unique presence on B lymphocytes, Siglec-2 is an attractive therapeutic target. Currently, there are numerous ongoing trials assessing the safety and efficacy of CD22-directed chimeric antigen receptor (CAR) therapies, particularly in children with relapsed or refractory B-cell leukemia. Additionally, the development of novel CARs, such as bispecific CD20/CD22 CARs and CD19/CD22 CARs, is underway.
电泳(SDS-PAGE)
1μg (R: reducing condition, N: non-reducing condition).
体积排阻色谱(SEC-HPLC)
![item.picture[0].fileOrgName](https://univ-pmc.oss-cn-shanghai.aliyuncs.com/product.imager.attribute/67609/6d7ef771-c444-4e17-ae10-07ec117bf8ba.png)
The purity of Siglec-2/CD22 His Tag Protein, Rat is more than 95% determined by SEC-HPLC.
引用文献(0)
评论(0)